BTC$62,495.00-2.10%
ETH$1,662.50-3.31%
USDT$0.99890.00%
BNB$576.53-2.03%
USDC$0.9998-0.01%
XRP$1.11-1.51%
SOL$69.43-3.23%
TRX$0.329-1.30%
FIGR_HELOC$1.03-0.16%
HYPE$62.14-5.95%
DOGE$0.0788-3.89%
USDS$0.9997+0.01%
RAIN$0.0156-2.27%
LEO$9.54+0.05%
ZEC$416.96-5.64%
XLM$0.1953-3.57%
BTC$62,495.00-2.10%
ETH$1,662.50-3.31%
USDT$0.99890.00%
BNB$576.53-2.03%
USDC$0.9998-0.01%
XRP$1.11-1.51%
SOL$69.43-3.23%
TRX$0.329-1.30%
FIGR_HELOC$1.03-0.16%
HYPE$62.14-5.95%
DOGE$0.0788-3.89%
USDS$0.9997+0.01%
RAIN$0.0156-2.27%
LEO$9.54+0.05%
ZEC$416.96-5.64%
XLM$0.1953-3.57%
BioNTech's $1.25 billion acquisition of CureVac creates a "German biotech champion" focused on mRNA-based cancer treatments, with CureVac shares surging 38% on the announcement.